Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07561294 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing
    • Enrollment target: estimated 350 to confirmed 366
    • Site details revised at 8 of 8 sites
    v4
  2. Site details revised at 7 of 8 sitesv3
  3. Recruitment opened
    • Start date changed from estimate of Apr 27, 2026 to Apr 29, 2026
    • Site details revised at 8 of 8 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
Trial Details
NCT Number NCT07561294
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Lyme Disease
Related terms Lyme Disease
Enrollment 366 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov